To test the hypothesis, we developed a BLM-induced pulmonary fibrosis mouse model, and demonstrated that not only amelioration of pulmonary inflammation but also inhibition of TGF-β1 signaling and EMT process were involved in the anti-fibrotic effects of iPS cells. Here, TGFB1 is linked to pulmonary fibrosis.